vs
Ginkgo Bioworks Holdings, Inc.（DNA）与MP Materials Corp.（MP）财务数据对比。点击上方公司名可切换其他公司
MP Materials Corp.的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.6倍（$52.7M vs $33.4M），MP Materials Corp.同比增速更快（-13.6% vs -23.8%），Ginkgo Bioworks Holdings, Inc.自由现金流更多（$-47.7M vs $-109.3M），过去两年MP Materials Corp.的营收复合增速更高（4.0% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
MP Materials Corp.是总部位于美国的稀土材料生产商，拥有并运营加利福尼亚州芒廷帕斯矿，这是西半球唯一在产的稀土开采及加工设施，所产核心材料可广泛应用于电动汽车、风力发电机、国防工业等多个关键领域。
DNA vs MP — 直观对比
营收规模更大
MP
是对方的1.6倍
$33.4M
营收增速更快
MP
高出10.2%
-23.8%
自由现金流更多
DNA
多$61.6M
$-109.3M
两年增速更快
MP
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $52.7M |
| 净利润 | — | $9.4M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | -7.0% |
| 净利率 | — | 17.9% |
| 营收同比 | -23.8% | -13.6% |
| 净利润同比 | — | 142.2% |
| 每股收益（稀释后） | $-1.41 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAMP
| Q4 25 | $33.4M | $52.7M | ||
| Q3 25 | $38.8M | $53.6M | ||
| Q2 25 | $49.6M | $57.4M | ||
| Q1 25 | $48.3M | $60.8M | ||
| Q4 24 | $43.8M | $61.0M | ||
| Q3 24 | $89.0M | $62.9M | ||
| Q2 24 | $56.2M | $31.3M | ||
| Q1 24 | $37.9M | $48.7M |
净利润DNAMP
| Q4 25 | — | $9.4M | ||
| Q3 25 | $-80.8M | $-41.8M | ||
| Q2 25 | $-60.3M | $-30.9M | ||
| Q1 25 | $-91.0M | $-22.6M | ||
| Q4 24 | — | $-22.3M | ||
| Q3 24 | $-56.4M | $-25.5M | ||
| Q2 24 | $-217.2M | $-34.1M | ||
| Q1 24 | $-165.9M | $16.5M |
营业利润率DNAMP
| Q4 25 | -211.9% | -7.0% | ||
| Q3 25 | -231.8% | -125.2% | ||
| Q2 25 | -132.1% | -76.5% | ||
| Q1 25 | -184.1% | -57.2% | ||
| Q4 24 | -236.3% | -72.1% | ||
| Q3 24 | -62.0% | -62.8% | ||
| Q2 24 | -396.7% | -171.1% | ||
| Q1 24 | -469.1% | -66.6% |
净利率DNAMP
| Q4 25 | — | 17.9% | ||
| Q3 25 | -207.9% | -78.0% | ||
| Q2 25 | -121.6% | -53.8% | ||
| Q1 25 | -188.2% | -37.2% | ||
| Q4 24 | — | -36.6% | ||
| Q3 24 | -63.3% | -40.5% | ||
| Q2 24 | -386.4% | -108.9% | ||
| Q1 24 | -437.3% | 33.9% |
每股收益（稀释后）DNAMP
| Q4 25 | $-1.41 | $0.07 | ||
| Q3 25 | $-1.45 | $-0.24 | ||
| Q2 25 | $-1.10 | $-0.19 | ||
| Q1 25 | $-1.68 | $-0.14 | ||
| Q4 24 | $-1.91 | $-0.12 | ||
| Q3 24 | $-1.08 | $-0.16 | ||
| Q2 24 | $-4.23 | $-0.21 | ||
| Q1 24 | $-3.32 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $1.2B |
| 总债务越低越好 | — | $998.7M |
| 股东权益账面价值 | $508.6M | $2.0B |
| 总资产 | $1.1B | $3.9B |
| 负债/权益比越低杠杆越低 | — | 0.50× |
8季度趋势，按日历期对齐
现金及短期投资DNAMP
| Q4 25 | $422.6M | $1.2B | ||
| Q3 25 | $495.5M | $1.1B | ||
| Q2 25 | $559.4M | $261.5M | ||
| Q1 25 | $325.3M | $198.3M | ||
| Q4 24 | $561.6M | $282.4M | ||
| Q3 24 | $616.2M | $284.4M | ||
| Q2 24 | $730.4M | $295.6M | ||
| Q1 24 | $840.4M | $296.5M |
总债务DNAMP
| Q4 25 | — | $998.7M | ||
| Q3 25 | — | $997.3M | ||
| Q2 25 | — | $910.8M | ||
| Q1 25 | — | $909.8M | ||
| Q4 24 | — | $908.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DNAMP
| Q4 25 | $508.6M | $2.0B | ||
| Q3 25 | $559.8M | $2.0B | ||
| Q2 25 | $613.0M | $1.0B | ||
| Q1 25 | $647.4M | $1.0B | ||
| Q4 24 | $716.1M | $1.1B | ||
| Q3 24 | $797.9M | $1.1B | ||
| Q2 24 | $833.1M | $1.1B | ||
| Q1 24 | $987.3M | $1.1B |
总资产DNAMP
| Q4 25 | $1.1B | $3.9B | ||
| Q3 25 | $1.2B | $3.8B | ||
| Q2 25 | $1.2B | $2.3B | ||
| Q1 25 | $1.3B | $2.4B | ||
| Q4 24 | $1.4B | $2.3B | ||
| Q3 24 | $1.5B | $2.3B | ||
| Q2 24 | $1.6B | $2.4B | ||
| Q1 24 | $1.6B | $2.4B |
负债/权益比DNAMP
| Q4 25 | — | 0.50× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | — | 0.88× | ||
| Q4 24 | — | 0.86× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $-46.9M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $-109.3M |
| 自由现金流率自由现金流/营收 | -142.8% | -207.4% |
| 资本支出强度资本支出/营收 | 0.0% | 118.5% |
| 现金转化率经营现金流/净利润 | — | -4.97× |
| 过去12个月自由现金流最近4个季度 | — | $-328.1M |
8季度趋势，按日历期对齐
经营现金流DNAMP
| Q4 25 | $-47.7M | $-46.9M | ||
| Q3 25 | $-31.6M | $-42.0M | ||
| Q2 25 | $-40.3M | $-3.7M | ||
| Q1 25 | $-51.5M | $-63.2M | ||
| Q4 24 | $-42.4M | $30.5M | ||
| Q3 24 | $-103.5M | $-6.8M | ||
| Q2 24 | $-84.4M | $30.8M | ||
| Q1 24 | $-89.3M | $-41.1M |
自由现金流DNAMP
| Q4 25 | $-47.7M | $-109.3M | ||
| Q3 25 | — | $-92.5M | ||
| Q2 25 | $-40.3M | $-32.7M | ||
| Q1 25 | $-59.1M | $-93.7M | ||
| Q4 24 | $-56.1M | $-11.2M | ||
| Q3 24 | $-118.6M | $-53.3M | ||
| Q2 24 | $-111.4M | $-15.6M | ||
| Q1 24 | $-96.0M | $-93.0M |
自由现金流率DNAMP
| Q4 25 | -142.8% | -207.4% | ||
| Q3 25 | — | -172.8% | ||
| Q2 25 | -81.2% | -56.9% | ||
| Q1 25 | -122.4% | -154.0% | ||
| Q4 24 | -128.0% | -18.3% | ||
| Q3 24 | -133.2% | -84.7% | ||
| Q2 24 | -198.2% | -50.1% | ||
| Q1 24 | -252.9% | -191.0% |
资本支出强度DNAMP
| Q4 25 | 0.0% | 118.5% | ||
| Q3 25 | 0.0% | 94.3% | ||
| Q2 25 | 0.1% | 50.5% | ||
| Q1 25 | 15.8% | 50.1% | ||
| Q4 24 | 31.3% | 68.3% | ||
| Q3 24 | 16.9% | 73.8% | ||
| Q2 24 | 48.1% | 148.7% | ||
| Q1 24 | 17.7% | 106.5% |
现金转化率DNAMP
| Q4 25 | — | -4.97× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -2.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
MP
| Materials Segment | $35.6M | 68% |
| Other | $17.1M | 32% |
